QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF) All Versions of this Article: 8/2/189    most recent 15228517-2005-010v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Prados, M. D. Articles by Kuhn, J. Search for Related Content PubMed PubMed Citation Social Bookmarking                   What's this?

A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study¹

University of California, San Francisco (M.D.P., K.L., S.C., M.K.N.), San Francisco, CA 94143; University of Texas M.D. Anderson Cancer Center, Houston, TX 77030 (W.K.A.Y., K.J., K.H.); University of Wisconsin Medical Center, Madison, WI 53792 (H.I.R., M.M.); National Institutes of Health, Bethesda, MD 20892 (H.F.); Dana-Farber/Brigham and Women's Cancer Center, Boston, MA 02115 (P.Y.W.); University of California, Los Angeles, Los Angeles, CA 90095 (T.C.); University of Virginia Health Science Center, Charlottesville, VA 22908 (D.S.); University of Michigan Medical Center, Ann Arbor, MI 48109 (H.G., L.J.); University of Texas Southwestern Medical Center, Dallas, TX 75390 (K.F.); and University of Texas Health Sciences Center, San Antonio, TX 78229 (J.K.); USA

² Address correspondence to Michael Prados, University of California, San Francisco, 400 Parnassus Avenue, Room A808, San Francisco, California 94143-0372 (pradosm{at}neurosurg.ucsf.edu).

The purpose of this study was to determine the response to CPT-11 administered every three weeks to adults with progressive malignant glioma, treated with or without enzyme-inducing antiepileptic drug (EIAED) therapy, at the recommended phase 2 dose determined from a previous phase 1 study. Adult patients age 18 or older with a KPS of 60 or higher who had measurable recurrent grade III anaplastic glioma (AG) or grade IV glioblastoma multiforme (GBM) were eligible. No more than one prior chemotherapy was allowed, either as adjuvant therapy or for recurrent disease. The CPT-11 dose was 350 mg/m² i.v. every three weeks in patients not on EIAED and 750 mg/m² in patients on EIAED therapy. Patients with stable or responding disease could be treated until tumor progression or a total of 12 months of therapy. The primary end point of the study was to determine whether CPT-11 could significantly delay tumor progression, using the rate of six-month progression-free survival (PFS-6). The trial was sized to be able to discriminate between a 15% and 35% rate for the GBM group alone and between a 20% and 40% rate for the entire cohort. There were 51 eligible patients, including 38 GBM and 13 AG patients, enrolled. The median age was 52 and 42 years, respectively. PFS-6 for the entire cohort was 17.6%. PFS-6 was 15.7% (95% confidence interval [CI], 0.07-0.31) for the GBM patients and 23% (95% CI, 0.07-0.52) for AG patients. Toxicity for the group included diarrhea and myelosuppression. We conclude that the recommended phase 2 dose of CPT-11 for patients with or without EIAED was ineffective on this schedule, in this patient population.

Key Words: clinical trial • irinotecan • phase 2 • recurrent malignant glioma

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. A. Jaeckle, K. Ballman, A. Furth, and J. C. Buckner Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma Neurology, October 13, 2009; 73(15): 1207 - 1213. [Abstract] [Full Text] [PDF]

				H. S. Friedman, M. D. Prados, P. Y. Wen, T. Mikkelsen, D. Schiff, L. E. Abrey, W.K. A. Yung, N. Paleologos, M. K. Nicholas, R. Jensen, et al. Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma J. Clin. Oncol., October 1, 2009; 27(28): 4733 - 4740. [Abstract] [Full Text] [PDF]

				M. C. Chamberlain, M. M. Mrugala, A. D. Norden, G. S. Young, and P. Y. Wen BEVACIZUMAB FOR RECURRENT MALIGNANT GLIOMAS: EFFICACY, TOXICITY, AND PATTERNS OF RECURRENCE Neurology, February 24, 2009; 72(8): 772 - 774. [Full Text] [PDF]

				J. J. Vredenburgh, A. Desjardins, D. A. Reardon, and H. S. Friedman Experience with irinotecan for the treatment of malignant glioma Neuro-oncol, January 1, 2009; 11(1): 80 - 91. [Abstract] [Full Text] [PDF]

				K. Jahnke, L. L. Muldoon, C. G. Varallyay, S. J. Lewin, D. F. Kraemer, and E. A. Neuwelt Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model Neuro-oncol, January 1, 2009; 11(2): 142 - 150. [Abstract] [Full Text] [PDF]

				E. C. Quant, A. D. Norden, J. Drappatz, A. Muzikansky, L. Doherty, D. LaFrankie, A. Ciampa, S. Kesari, and P. Y. Wen Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab Neuro-oncol, January 1, 2009; 11(5): 550 - 555. [Abstract] [Full Text] [PDF]

				A. Desjardins, D. A. Reardon, J. E. Herndon II, J. Marcello, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, J. Sampson, L. Bailey, et al. Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas Clin. Cancer Res., November 1, 2008; 14(21): 7068 - 7073. [Abstract] [Full Text] [PDF]

				S. M. Chang, K. R. Lamborn, J. G. Kuhn, W.K. A. Yung, M. R. Gilbert, P. Y. Wen, H. A. Fine, M. P. Mehta, L. M. DeAngelis, F. S. Lieberman, et al. Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium Neuro-oncol, August 1, 2008; 10(4): 631 - 642. [Abstract] [Full Text] [PDF]

				S. A. Grossman, K. A. Carson, S. Phuphanich, T. Batchelor, D. Peereboom, L. B. Nabors, G. Lesser, F. Hausheer, J. G. Supko, and for the New Approaches to Brain Tumor Therapy CNS Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas Neuro-oncol, August 1, 2008; 10(4): 608 - 616. [Abstract] [Full Text] [PDF]

				V. K. Puduvalli, P. Giglio, M. D. Groves, K. R. Hess, M. R. Gilbert, S. Mahankali, E. F. Jackson, V. A. Levin, C. A. Conrad, S. H. Hsu, et al. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme Neuro-oncol, April 1, 2008; 10(2): 216 - 222. [Abstract] [Full Text] [PDF]

				M. C. Chamberlain Bevacizumab Plus Irinotecan in Recurrent Glioblastoma J. Clin. Oncol., February 20, 2008; 26(6): 1012 - 1013. [Full Text] [PDF]

				S. Sathornsumetee, Y. Cao, J. E. Marcello, J. E. Herndon II, R. E. McLendon, A. Desjardins, H. S. Friedman, M. W. Dewhirst, J. J. Vredenburgh, and J. N. Rich Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan J. Clin. Oncol., January 10, 2008; 26(2): 271 - 278. [Abstract] [Full Text] [PDF]

				J. J. Vredenburgh, A. Desjardins, J. E. Herndon II, J. Marcello, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, J. Sampson, et al. Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme J. Clin. Oncol., October 20, 2007; 25(30): 4722 - 4729. [Abstract] [Full Text] [PDF]

				J. J. Vredenburgh, A. Desjardins, J. E. Herndon II, J. M. Dowell, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, M. Wagner, et al. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma Clin. Cancer Res., February 15, 2007; 13(4): 1253 - 1259. [Abstract] [Full Text] [PDF]

				M. C. Chamberlain, W. B. Pope, and T. Cloughesy MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy Neurology, December 12, 2006; 67(11): 2089 - 2089. [Full Text] [PDF]